NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Zydus Lifesciences Announces ₹1,100 Crore Share Buyback at ₹1,150 Per Share
Zydus Lifesciences has issued a public announcement for the buyback of up to 95,65,217 equity shares through the tender offer route. The buyback price is set at ₹1,150 per share, representing a total commitment of up to ₹1,100 crores. This corporate action aims to return surplus cash to shareholders on a proportionate basis. The announcement follows the Board's approval on May 19, 2026, and complies with SEBI Buy-Back Regulations.
முக்கிய அம்சங்கள்
Buyback of up to 95,65,217 fully paid-up equity shares of face value ₹1 eachBuyback price fixed at ₹1,150 per share payable in cashTotal aggregate buyback amount not to exceed ₹1,100 croresExecution via the tender offer route on a proportionate basis for eligible shareholders
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming record date to determine eligibility and evaluate the premium of the ₹1,150 offer price against the current market price for potential tendering.
Zydus Lifesciences Approves ₹1,100 Crore Buyback at ₹1,150 Per Share
Zydus Lifesciences has approved a share buyback of up to 95,65,217 equity shares at a price of ₹1,150 per share, representing a total outlay of ₹1,100 crores. The buyback will be conducted through the tender offer route, making it accessible to all shareholders holding shares as of the record date, May 29, 2026. The buyback size represents 3.84% of the company's consolidated free reserves and paid-up capital as of March 31, 2026. This capital return initiative is expected to support the stock price and improve earnings per share.
முக்கிய அம்சங்கள்
Buyback price fixed at ₹1,150 per share, representing a premium over current market levels.Total buyback size capped at ₹1,100 crores, excluding taxes and transaction costs.Up to 95,65,217 shares (0.95% of total equity) to be repurchased via tender offer.Record date for eligibility is set for Friday, May 29, 2026.15% of the buyback is reserved for small shareholders as per SEBI regulations.
👀 கவனிக்க வேண்டியவை
Investors should monitor the stock price relative to the ₹1,150 offer price and ensure they hold shares by the May 29 record date if they wish to participate in the tender offer.
Zydus Lifesciences Declares Re. 1 Final Dividend; Sets July 24, 2026 as Record Date
Zydus Lifesciences has recommended a final dividend of Re. 1 per equity share, representing 100% of the face value for the financial year ended March 31, 2026. The Board has fixed July 24, 2026, as the record date to determine shareholder eligibility for this payout. The dividend is subject to shareholder approval at the 31st Annual General Meeting scheduled for August 11, 2026. If approved, the company plans to distribute the dividend payment on or around August 14, 2026.
முக்கிய அம்சங்கள்
Final dividend of Re. 1 per equity share (100% of face value) for FY26.Record date for dividend entitlement fixed as July 24, 2026.31st Annual General Meeting (AGM) scheduled for August 11, 2026.Dividend payment expected to be processed on or around August 14, 2026.
👀 கவனிக்க வேண்டியவை
Investors seeking to benefit from the dividend should ensure they hold the stock before the ex-dividend date, typically one day prior to the July 24 record date. The dividend yield should be assessed relative to the current market price for total return expectations.
Zydus Life Q4 Net Profit Up 15%, Announces ₹1,100 Cr Buyback at 16% Premium
Zydus Lifesciences reported a strong Q4 FY26 with revenue growing 16.2% YoY to ₹75,870 mn and adjusted net profit rising 14.6% to ₹15,929 mn. The company's EBITDA margins expanded by 110 bps to 33.7%, driven by robust performance in India formulations and a 61% surge in Consumer Wellness. A major highlight for shareholders is the board's approval of an ₹11,000 mn share buyback at ₹1,150 per share, representing a 16% premium. Furthermore, the company is strengthening its US specialty presence through the $166 mn acquisition of Assertio Holdings.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue grew 16.2% YoY to ₹75,870 mn; FY26 Revenue up 16.8% to ₹2,71,484 mnAdjusted Net Profit for Q4 rose 14.6% YoY to ₹15,929 mn with EBITDA margins improving to 33.7%Approved ₹11,000 mn share buyback at ₹1,150 per share, a 16% premium to the closing price of May 18, 2026India Formulations business grew 14% YoY, while Consumer Wellness surged 61% YoY in Q4Acquisition of US-based Assertio Holdings for $166 mn to strengthen specialty and oncology portfolio
👀 கவனிக்க வேண்டியவை
Investors should benefit from the premium buyback and strong margin expansion, which signals high management confidence. The strategic shift toward US specialty products via the Assertio acquisition helps mitigate pricing pressures in the US generics market.
Zydus Lifesciences Limited reported a strong performance for Q4 FY26 with total revenues from operations growing 16% YoY to Rs. 75,870 mn. EBITDA for the quarter increased by 20% YoY to Rs. 25,544 mn, with margins expanding by 110 bps to 33.7%. Net profit (excluding exceptional items) grew 15% YoY to Rs. 15,929 mn. Additionally, the Board has approved a share buyback of up to Rs. 11,000 mn at Rs. 1,150 per share, representing a 16% premium to the closing price on May 18, 2026.
முக்கிய அம்சங்கள்
Q4 FY26 revenue from operations grew 16% YoY to Rs. 75,870 mn, while full-year FY26 revenue reached Rs. 2,71,484 mn.EBITDA margin expanded by 110 bps YoY to 33.7% in Q4 FY26, with EBITDA rising 20% YoY to Rs. 25,544 mn.India formulations business grew 14% YoY to Rs. 17,528 mn, outperforming the market in key chronic therapies.Board approved a share buyback of up to Rs. 11,000 mn at Rs. 1,150 per equity share.Signed a definitive agreement to acquire US-based Assertio Holdings Inc. for a consideration of US$ 166 mn.
👀 கவனிக்க வேண்டியவை
Investors should view this as a highly positive development given the robust margin expansion, strong domestic growth, and value-accretive buyback at a premium. The acquisition of Assertio Holdings also strengthens the US specialty pipeline, making the stock a strong hold/buy on dips candidate.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Zydus Lifesciences Re-appoints Dr. Sharvil Patel as MD and Appoints Kulin Lalbhai to Board
Zydus Lifesciences has approved the re-appointment of Dr. Sharvil P. Patel as Managing Director for a further five-year term effective from April 1, 2027, ensuring leadership continuity. The board also appointed Mr. Kulin S. Lalbhai, a Harvard MBA and current Director at Arvind Limited, as an Independent Director for a five-year term starting May 19, 2026. These appointments, subject to shareholder approval, aim to strengthen the company's strategic leadership and governance. Dr. Patel has been instrumental in Zydus's recent breakthroughs in complex therapies like NASH treatment.
முக்கிய அம்சங்கள்
Dr. Sharvil P. Patel re-appointed as Managing Director for a 5-year term from April 1, 2027, to March 31, 2032.Mr. Kulin S. Lalbhai appointed as Independent Director for a 5-year term effective May 19, 2026.Dr. Patel's leadership has seen Zydus become the first globally to announce a treatment for non-cirrhotic NASH.Mr. Lalbhai brings extensive experience in digital transformation and consumer-facing businesses from his tenure at Arvind Limited.Both appointments are subject to shareholder approval via special resolution at the upcoming Annual General Meeting.
👀 கவனிக்க வேண்டியவை
Investors should view the leadership continuity and the addition of a high-caliber independent director as a positive sign for long-term governance and strategic execution.
Zydus Lifesciences has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The Board has recommended a final dividend of Re. 1 per equity share (100% of face value), pending shareholder approval at the AGM on August 11, 2026. Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified audit opinion, indicating no material discrepancies in the financial reporting.
முக்கிய அம்சங்கள்
Recommended a final dividend of Re. 1 per equity share of Re. 1 each (100% payout).Statutory auditors Deloitte submitted audit reports with an unmodified opinion for FY26.Annual General Meeting (AGM) is scheduled for Tuesday, August 11, 2026.Trading window for insiders to reopen on May 22, 2026, following the results announcement.
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed financial tables on the company website to assess year-on-year growth in revenue and margins. The dividend provides a steady return, but the stock's movement will likely depend on the underlying earnings growth revealed in the full report.
Zydus Lifesciences to Acquire US-based Assertio Holdings for $166.4 Million
Zydus Lifesciences, through its subsidiary Zydus Worldwide DMCC, has entered into a definitive agreement to acquire 100% of U.S.-based Assertio Holdings for approximately USD 166.4 million in cash. The acquisition price of USD 23.50 per share provides Zydus with an immediate specialty oncology commercial footprint in the U.S. market. Assertio's primary asset, ROLVEDON®, is a USFDA-approved biologic that generated USD 68.23 million in revenue during CY2025. The transaction is structured as a tender offer followed by a merger and is expected to close in FY 2026-27.
முக்கிய அம்சங்கள்
Total acquisition consideration of approximately USD 166.4 million at USD 23.50 per share in cash.Acquisition includes ROLVEDON®, a USFDA-approved long-acting G-CSF biologic for cancer patients.Assertio's ROLVEDON® revenue grew from USD 60.09 million in CY2024 to USD 68.23 million in CY2025.Provides access to 170+ community oncology accounts and established buy-and-bill infrastructure in the U.S.The transaction is expected to be completed within the financial year 2026-27 subject to regulatory approvals.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant strategic expansion into the high-margin U.S. specialty oncology segment. Monitor the progress of the tender offer and the integration of Assertio's commercial platform into Zydus's global operations.
Zydus Lifesciences Unit 9 Biologics Plant Receives 7 USFDA Observations
The USFDA conducted a GMP surveillance inspection at Zydus Lifesciences' Unit 9 facility in Ahmedabad from April 27 to May 5, 2026. The inspection concluded with seven observations, though notably, there were no findings related to data integrity. This facility, located at Zydus Biotech Park, is critical for the company's biologics injectable portfolio. The company has committed to addressing these observations expeditiously to ensure continued compliance.
முக்கிய அம்சங்கள்
USFDA GMP surveillance inspection conducted at Unit 9, Zydus Biotech Park, Ahmedabad.The inspection took place over 9 days from April 27 to May 5, 2026.Audit concluded with 7 observations but zero data integrity issues.Company is working closely with the USFDA to address observations expeditiously.
👀 கவனிக்க வேண்டியவை
Investors should monitor the nature of the 7 observations and the subsequent USFDA classification (VAI or OAI). While the lack of data integrity issues is positive, the number of observations warrants a cautious watch on potential clearance timelines.
Zydus Lifesciences Subsidiary Acquires 100% Stake in Aptitude Orthopedie for Euro 360,000
Zydus Lifesciences, through its indirect subsidiary Amplitude SAS, has acquired 100% of Aptitude Orthopedie, a French medical equipment distributor. The acquisition, valued at Euro 360,000, aims to internalize commercial capabilities that were previously outsourced to third-party agents. This strategic move is expected to eliminate ongoing commission and business-development fees, thereby reducing long-term selling and distribution costs in specific French regions. While the deal size is small relative to Zydus's overall operations, it reflects a focus on margin optimization in international markets.
முக்கிய அம்சங்கள்
Acquisition of 100% share capital (5,000 shares) for a cash consideration of Euro 360,000.Target entity Aptitude Orthopedie reported a turnover of Euro 364,000 for the fiscal year ending June 30, 2025.Strategic objective to internalize sales capabilities and eliminate third-party commission fees in France.Aptitude Orthopedie has been an exclusive commercial agent for Zydus's subsidiary in French departments 14 and 50 since 2016.The transaction was completed on April 30, 2026, with no regulatory approvals required.
👀 கவனிக்க வேண்டியவை
This is a minor bolt-on acquisition aimed at improving operational efficiency and margins in the French market. Investors should monitor if similar cost-saving internalizations are planned for other international territories.
Zydus Lifesciences Gets DCGI Nod for Phase III Trials of Anti-Malarial Drug Zintrodiazine
Zydus Lifesciences has received DCGI approval to initiate two Phase III clinical trials for Zintrodiazine, a novel anti-malarial candidate targeting P. falciparum and P. vivax. The trials will involve a total of 1,041 patients across India to evaluate efficacy, safety, and tolerability against drug-resistant strains. This development, in collaboration with Medicines for Malaria Venture (MMV), addresses the global challenge of artemisinin resistance. Successful completion could position Zydus as a leader in next-generation malaria treatments, addressing a market where over 1,80,000 cases were reported in India last year.
முக்கிய அம்சங்கள்
Received DCGI approval for two Phase III trials involving 651 and 390 patients respectively.Zintrodiazine targets both P. falciparum and P. vivax, including drug-resistant strains.The drug is being developed as an alternative to current artemisinin-based combination therapies (ACTs).Collaboration with Medicines for Malaria Venture (MMV) has been ongoing since 2016.Primary objective is evaluating efficacy via PCR-adjusted adequate clinical and parasitological response (ACPR).
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of these Phase III trials as they represent a significant milestone in Zydus's innovation-led R&D pipeline. Success in these trials could open substantial global market opportunities given the rising resistance to existing malaria treatments.
Zydus Lifesciences Receives USFDA EIR for Ahmedabad Oncology Injectable Facility
Zydus Lifesciences has received the Establishment Inspection Report (EIR) and approval letter from the USFDA for its oncology injectable manufacturing facility in SEZ1, Ahmedabad. This follows a Pre-Approval Inspection (PAI) conducted between November 4 and November 13, 2025, specifically for a new isolator injectable line. The successful closure of this inspection clears a major regulatory hurdle for the facility. This approval is expected to support the company's growth in the high-value oncology segment in the US market.
முக்கிய அம்சங்கள்
Received EIR and approval letter from USFDA for the SEZ1 Ahmedabad oncology siteInspection was a Pre-Approval Inspection (PAI) for a new isolator injectable lineThe USFDA audit was conducted over a 10-day period from November 4 to November 13, 2025Approval facilitates future commercial launches of oncology injectables from this facility
👀 கவனிக்க வேண்டியவை
This is a positive regulatory milestone that strengthens Zydus's specialized manufacturing capabilities. Investors should monitor for subsequent ANDA approvals linked to this facility as they will drive future revenue growth.
Zydus Receives USFDA Approval for Dapagliflozin; Targets $10.2bn US Market
Zydus Lifesciences has received final USFDA approval for Dapagliflozin Tablets (5 mg and 10 mg), the generic version of Farxiga used for treating Type 2 diabetes. This approval is highly significant as the drug has an annual market size of approximately USD 10.2 billion in the United States. Zydus is also eligible for 180 days of shared generic drug exclusivity, which usually results in higher pricing power and margins during the launch phase. The product will be manufactured at the company's SEZ facility in Ahmedabad, further strengthening its US generic portfolio.
முக்கிய அம்சங்கள்
Final USFDA approval received for Dapagliflozin Tablets (5 mg and 10 mg) for Type 2 diabetes.Eligible for 180 days of shared generic drug exclusivity in the US market.Targets a massive US market with annual sales of USD 10.2 billion according to IQVIA MAT February 2026 data.Production to be localized at the group’s formulation manufacturing facility at SEZ, Ahmedabad.Zydus now has 436 total USFDA approvals and has filed 505 ANDAs since FY 2003-04.
👀 கவனிக்க வேண்டியவை
Investors should view this as a major growth catalyst for Zydus's US business given the multi-billion dollar market size and exclusivity period. Monitor the official launch date and subsequent market share gains in the SGLT2 inhibitor segment.
Zydus Lifesciences Launches Semaglutide at Rs 2,200/Month for Diabetes and Obesity
Zydus Lifesciences has launched generic Semaglutide in India under the brand names SEMAGLYN, MASHEMA, and ALTERME following patent expiry. The drug is approved for both Type 2 Diabetes and Obesity, targeting a massive market of 8.9 crore diabetic adults in India. A key differentiator is the introduction of a reusable multi-dose pen device, which significantly lowers the average monthly therapy cost to approximately Rs. 2,200. This move positions Zydus to capture significant market share in the high-growth GLP-1 segment through aggressive pricing and delivery innovation.
முக்கிய அம்சங்கள்
Launched Semaglutide injection for Type 2 Diabetes and Obesity under three distinct brand namesIntroduced a first-in-India reusable multi-dose pen device for which the company holds exclusive rightsPriced the treatment at an average monthly cost of approximately Rs. 2,200, making it highly competitiveTargeting a domestic market of 8.9 crore diabetic adults and a rising obese populationProduct will be manufactured at the Zydus Biotech Park in Ahmedabad using a 15mg/3ml cartridge
👀 கவனிக்க வேண்டியவை
Investors should monitor the adoption rate of these brands as they represent a major growth lever in the chronic care segment. The competitive pricing and innovative delivery system could lead to significant market share gains in the Indian GLP-1 market.
Zydus Lifesciences Launches Aerolife Mini™, India's First Foldable Inhaler Spacer
Zydus Lifesciences has introduced Aerolife Mini™, a next-generation pMDI enhancer, through an exclusive licensing agreement with AeroDel Technology. The device is India's first portable and foldable spacer, designed to solve the issue where 94% of patients make critical errors using standard inhalers. This launch targets the growing burden of asthma and COPD in India, aiming to improve drug deposition and patient compliance. The move aligns with Zydus' strategy to build a differentiated respiratory franchise using patient-centric drug-device innovations.
முக்கிய அம்சங்கள்
India's first foldable and portable next-gen pMDI enhancer launched under exclusive license.Targets a critical healthcare gap where 94% of patients make errors in inhaler technique.Developed in partnership with AeroDel Technology, supported by India's Dept. of Science and Technology.Part of Zydus' innovation-led strategy involving 1,500 scientists and 29,000 global employees.
👀 கவனிக்க வேண்டியவை
This launch strengthens Zydus' position in the high-growth respiratory segment; investors should monitor its impact on the company's domestic formulation margins and market share.
Zydus and Torrent Pharma Partner to Co-Market Semaglutide Injection in India
Zydus Lifesciences and Torrent Pharma have entered into a licensing and supply agreement to co-market an innovative Semaglutide formulation in India. Zydus will manufacture the 15 mg/3 ml injection and receive an upfront licensing fee from Torrent Pharma. The product, administered via a reusable pen, targets Type 2 diabetes and chronic weight management. This partnership leverages Zydus's R&D capabilities and Torrent's extensive distribution network in chronic therapies to capture the high-growth GLP-1 market.
முக்கிய அம்சங்கள்
Zydus developed an innovative 15 mg/3 ml Semaglutide formulation with a patient-friendly reusable pen device.Torrent Pharma to pay an upfront licensing fee for semi-exclusive rights to market the product under the brand SEMBOLIC.Zydus will market the product under three brands: SEMAGLYN, MASHEMA, and ALTERME.The therapy targets adults with Type 2 diabetes and chronic weight management for those with BMI ≥30 or ≥27 with comorbidities.Torrent Pharma brings a strong field force and Top 5 ranking in Cardiovascular and CNS segments to the partnership.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for both companies as they enter the lucrative GLP-1 market in India. Zydus benefits from manufacturing volumes and licensing fees, while Torrent strengthens its leadership in chronic disease management.
Zydus and Lupin Partner to Co-Market Innovative Semaglutide Injection in India
Zydus Lifesciences has entered into a licensing and supply agreement with Lupin to co-market its innovative Semaglutide Injection (15 mg/3 ml) in the Indian market. Under the terms, Lupin will pay Zydus upfront licensing fees and milestone payments for semi-exclusive rights to market the product. This partnership leverages Zydus's product development and Lupin's extensive distribution network to target the high-growth diabetes and weight management segments. The product will be launched under multiple brand names by both companies, featuring a patient-friendly reusable pen device.
முக்கிய அம்சங்கள்
Lupin to pay Zydus upfront licensing fees and milestone-based payments for co-marketing rights.Product is a 15 mg/3 ml Semaglutide Injection indicated for Type 2 diabetes and chronic weight management.Zydus will market the product under three brands: SEMAGLYN, MASHEMA, and ALTERME.Lupin will market the product under two brands: Semanext and Lupin’s Livarise.Targets obesity management for adults with BMI of 30 kg/m2 or greater, or 27 kg/m2 with comorbidities.
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue contribution from milestone payments and the market share gains in the competitive GLP-1 segment in India. This collaboration strengthens Zydus's domestic portfolio and validates its R&D capabilities in complex injectables.
Zydus Subsidiary Sentynl Licenses Progerinin for Rare Disease; Phase 2A Data Due 1H 2026
Zydus Lifesciences' US subsidiary, Sentynl Therapeutics, has entered into a licensing agreement with Korean firm PRG S&T for Progerinin (SLC-D011), a treatment for the ultra-rare genetic disorder Hutchinson-Gilford Progeria Syndrome (HGPS). The drug candidate has already received FDA Orphan Drug designation and is currently in Phase 2A clinical trials, with results expected by the end of June 2026. Upon meeting specific milestones, Sentynl will acquire full rights to the molecule, making it their second therapy for HGPS. This move strengthens Zydus's presence in the high-value, specialized rare disease market in the United States.
முக்கிய அம்சங்கள்
Sentynl Therapeutics to license and potentially acquire full rights to Progerinin (SLC-D011) for HGPS.The molecule is currently in Phase 2A clinical trials with data readout expected in 1H 2026.Progerinin has already been granted Orphan Drug designation by the US FDA.In animal models, the drug increased lifespan by 8-10 weeks, a significant improvement over the 16.8-week average lifespan in control groups.The agreement allows Sentynl to immediately advance clinical development and expand its rare disease portfolio.
👀 கவனிக்க வேண்டியவை
Investors should monitor the Phase 2A trial results in 1H 2026 as a key catalyst for the specialty pipeline. This acquisition reinforces Zydus's strategy of moving into high-margin, low-competition niche segments in the US market.
Zydus Lifesciences' Desidustat Receives NMPA Approval in China for Renal Anaemia
Zydus Lifesciences' innovative drug Desidustat has received approval from China's NMPA for treating anaemia in Chronic Kidney Disease (CKD) patients. Licensed to China Medical System Holdings (CMS) in 2020, the drug addresses a significant unmet need for over 120 million CKD patients in China. Desidustat is an oral HIF-PHI, offering better compliance than traditional treatments, and has already treated over 100,000 patients in India since its 2022 launch. This approval follows successful Phase III clinical trials that met primary efficacy endpoints for hemoglobin maintenance.
முக்கிய அம்சங்கள்
NMPA approval granted for Desidustat to treat renal anaemia in non-dialysis adult CKD patients in China.The drug targets a massive patient base of approximately 120 million CKD sufferers in the Chinese market.Zydus has already successfully treated more than 100,000 patients in India with the drug under the brand Oxemia™.Phase III trial results showed the drug maintains Hb levels within target ranges with a favorable safety profile.
👀 கவனிக்க வேண்டியவை
This regulatory win strengthens Zydus's position in the global innovative drug space and opens a high-volume revenue stream. Investors should monitor the commercial rollout in China and subsequent royalty or milestone income.
Zydus Lifesciences Receives USFDA Approval for Cevimeline Hydrochloride Capsules 30mg
Zydus Lifesciences has received final USFDA approval for Cevimeline Hydrochloride Capsules 30mg, used to treat dry mouth associated with Sjögren’s syndrome. The product will be manufactured at the company's SEZ-II facility in Ahmedabad and targets a market with annual sales of USD 26.9 million as of January 2026. This approval brings the group's total USFDA approvals to 436, reflecting a strong track record in the US generic market. The company has filed a total of 505 ANDAs since the commencement of its filing process in FY 2003-04.
முக்கிய அம்சங்கள்
Final USFDA approval for Cevimeline Hydrochloride Capsules 30mg (Generic for Evoxac®)Targets an addressable market size of USD 26.9 million according to IQVIA MAT Jan-26 dataProduction to be localized at the Group’s manufacturing facility at SEZ-II, AhmedabadTotal USFDA approvals reach 436 with 505 ANDAs filed as of December 31, 2025
👀 கவனிக்க வேண்டியவை
This is a positive incremental development for Zydus's US portfolio; investors should monitor the company's ability to maintain its high rate of ANDA approvals and successful product launches.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
